Stonepine Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Stonepine Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50	Closed	-$1.27K	–	22
2023 Q1	$1.27K	Buy	+50	New	+$1.42K	﹤0.01%	22
2022 Q3	–	Sell	-10,422	Closed	-$102K	–	21
2022 Q2	$102K	Sell	10,422 -114,404	-92%	-$1.41M	0.05%	25
2022 Q1	$2.08M	Buy	124,826 +9,249	+8%	+$157K	0.86%	23
2021 Q4	$2.94M	Buy	115,577 +76,436	+195%	+$2.38M	1.35%	16
2021 Q3	$1.75M	Sell	39,141 -21,423	-35%	-$814K	0.8%	20
2021 Q2	$2.45M	Buy	+60,564	New	+$2.56M	1.28%	20
2020 Q2	–	Sell	-65,149	Closed	-$3.23M	–	16
2020 Q1	$3.23M	Buy	+65,149	New	+$3.9M	3.42%	16
2018 Q4	–	Sell	-32,807	Closed	-$2.89M	–	24
2018 Q3	$2.89M	Buy	32,807 +11,530	+54%	+$1.02M	1.69%	18
2018 Q2	$2.21M	Buy	+21,277	New	+$2.01M	1.34%	19

Other funds holding CDTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Stonepine Capital Management's CDTX Position: Q2 2023 in Review

Stonepine Capital Management sold out of Cidara Therapeutics (CDTX) in Q2 2023, closing a stake of 50 shares — an estimated $1.27K sold.

Stonepine Capital Management first reported a position in CDTX in Q2 2018 and held it in 9 quarters. The position peaked at $3.23M in Q1 2020. 52 funds tracked by Wall St. Rank hold CDTX as of Q2 2023.

Stonepine Capital Management reported no remaining Cidara Therapeutics position as of Q2 2023 after selling out during the quarter.
Stonepine Capital Management sold 50 Cidara Therapeutics shares in Q2 2023, an estimated $1.27K.
Stonepine Capital Management first reported a position in Cidara Therapeutics in Q2 2018 and held it in 9 quarters.
Stonepine Capital Management's Cidara Therapeutics position peaked at $3.23M in Q1 2020.
52 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2023.

Based on Stonepine Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.